Chronic hepatitis C virus (HCV) infection is an important risk factor for hepatocellular carcinoma (HCC). Despite effective antiviral therapies, the risk for HCC is decreased but not eliminated after a sustained virologic response (SVR) to direct-acting antiviral (DAA) agents, and the risk is higher in patients with advanced fibrosis. We investigated HCV-induced epigenetic alterations that might affect risk for HCC after DAA treatment in patients and mice with humanized livers.
Authors: Nourdine Hamdane, Frank Jühling, Emilie Crouchet, Houssein El Saghire, Christine Thumann, Marine A Oudot, Simonetta Bandiera, Antonio Saviano, Clara Ponsolles, Armando Andres Roca Suarez, Shen Li, Naoto Fujiwara, Atsushi Ono, Irwin Davidson, Nabeel Bardeesy, Christian Schmidl, Christoph Bock, Catherine Schuster, Joachim Lupberger, François Habersetzer, Michel Doffoël, Tullio Piardi, Daniele Sommacale, Michio Imamura, Takuro Uchida, Hideki Ohdan, Hiroshi Aikata, Kazuaki Chayama, Tujana Boldanova, Patrick Pessaux, Bryan C Fuchs, Yujin Hoshida, Mirjam B Zeisel, François H T Duong, Thomas F Baumert
Read publication